🇺🇸 FDA
Patent

US 9272023

Use of ixolaris, a tissue factor inhibitor, for inhibiting angiogenesis

granted A61KA61K38/1767A61K38/57

Quick answer

US patent 9272023 (Use of ixolaris, a tissue factor inhibitor, for inhibiting angiogenesis) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/1767, A61K38/57, A61K45/06, A61P